The Cancer-testis Antigen A-kinase Anchor Protein 3 Facilitates Breast Cancer Progression Via Activation of the PTEN/PI3K/AKT/mTOR Signaling
Overview
Affiliations
The cancer-testis antigen A-kinase anchor protein 3 (AKAP3) has been shown to have a strong association with breast cancer (BC). However, its role in BC progression received scant attention. We aimed to explore the prognostic implication of aberrant AKAP3 expression for a better knowledge of BC progression and improved treatment. AKAP3 expression was quantitated using tissue microarrays and immunohistochemistry (IHC). Cell viability, invasion, migration, apoptosis, and expressions of PTEN/PI3K/AKT/mTOR signaling components were assessed in AKAP3-overexpressed or si-AKAP3-transfected BC cells. Finally, elevated AKAP3 expression was observed in BC versus paracancerous tissues. BC patients with high AKAP3 expression showed a worse prognosis than low expression patients ( < 0.0001). AKAP3 overexpressions fueled cell growth, proliferation, migration, and invasion in HCC1937 and MDA-MB-468 BC cell lines, alongside increased expressions of PI3K/AKT/mTOR signaling components and PTEN suppression. These effects were pronouncedly reversed, together with elevated apoptosis, in cells transfected with si-AKAP3. Therefore, AKAP3 is upregulated in BC and promotes BC cell growth, invasion, and migration via PTEN/PI3K/AKT/mTOR signaling activation. It may serve as a prognosis indicator for BC survival.
Glutathione‑degrading enzymes in the complex landscape of tumors (Review).
Zhang T, Yao C, Zhou X, Liu S, Qi L, Zhu S Int J Oncol. 2024; 65(1).
PMID: 38847236 PMC: 11173371. DOI: 10.3892/ijo.2024.5660.
Li T, Huang M, Sun N, Hua X, Chen R, Xie Q J Exp Clin Cancer Res. 2024; 43(1):50.
PMID: 38365726 PMC: 10874020. DOI: 10.1186/s13046-024-02966-4.
Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers.
Zhang L, Ye B, Chen Z, Chen Z Acta Pharm Sin B. 2023; 13(3):982-997.
PMID: 36970215 PMC: 10031261. DOI: 10.1016/j.apsb.2022.10.002.